{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:13Z","timestamp":1790351833564,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1378\/chest.130.4.1117","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T15:40:00Z","timestamp":1160581200000},"page":"1117-1128","source":"Crossref","is-referenced-by-count":150,"title":["Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?"],"prefix":"10.1016","volume":"130","author":[{"given":"Maureen P.M.H.","family":"Rutten-van M\u00f6lken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Oostenbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta U.","family":"Monz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.130.4.1117_bib1","author":"Gold","year":"1996"},{"key":"10.1378\/chest.130.4.1117_bib2","article-title":"Canadian Coordinating Office for Health Technology Assessment","year":"1997","journal-title":"Guidelines for economic evaluation of pharmaceuticals"},{"key":"10.1378\/chest.130.4.1117_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-199507010-00001","article-title":"A proposal for Italian guidelines in pharmacoeconomics","volume":"7","author":"Garattini","year":"1995","journal-title":"Pharmacoeconomics"},{"key":"10.1378\/chest.130.4.1117_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200422040-00005","article-title":"The NICE reference case requirement. Implications for drug manufacturers and health systems","volume":"22","author":"Langley","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1378\/chest.130.4.1117_bib5","author":"Brooks","year":"2003"},{"key":"10.1378\/chest.130.4.1117_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1378\/chest.130.4.1117_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1378\/chest.108.6.1594","article-title":"The cost-effectiveness of lung transplantation: a pilot study","volume":"108","author":"Ramsey","year":"1995","journal-title":"Chest"},{"key":"10.1378\/chest.130.4.1117_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1378\/chest.113.1.124","article-title":"Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis","volume":"113","author":"Al","year":"1998","journal-title":"Chest"},{"key":"10.1378\/chest.130.4.1117_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s001340050879","article-title":"Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analyses","volume":"25","author":"Anon","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1378\/chest.130.4.1117_bib10","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1164\/ajrccm.164.11.2003151","article-title":"The cost effectiveness of early treatment with fluticasone propionate 250 mcg twice a day in subjects with obstructive airway disease: results of the DIMCA program","volume":"164","author":"Van den Boom","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.130.4.1117_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/thorax.56.10.779","article-title":"Cost effectiveness of an outpatient multidisciplinary rehabilitation programme","volume":"56","author":"Griffiths","year":"2001","journal-title":"Thorax"},{"key":"10.1378\/chest.130.4.1117_bib12","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMsa030448","article-title":"National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.130.4.1117_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1600-6143.2004.00479.x","article-title":"Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease","volume":"4","author":"Groen","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1378\/chest.130.4.1117_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1524-4733.2005.03086.x","article-title":"Probabilistic Markov model to asses the cost-effectiveness of tiotropium in COPD patients in different countries","volume":"8","author":"Oostenbrink","year":"2005","journal-title":"Value Health"},{"key":"10.1378\/chest.130.4.1117_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjmed.2003.09.027","article-title":"Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity","volume":"116","author":"Sin","year":"2004","journal-title":"Am J Med"},{"key":"10.1378\/chest.130.4.1117_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1524-4733.2004.72318.x","article-title":"A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease","volume":"7","author":"Borg","year":"2004","journal-title":"Value Health"},{"key":"10.1378\/chest.130.4.1117_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1183\/09031936.05.00122004","article-title":"A dynamic population model of disease progression in chronic obstructive pulmonary disease","volume":"26","author":"Hoogendoorn-Lips","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.130.4.1117_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/COPD-200026934","article-title":"Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial","volume":"1","author":"Decramer","year":"2004","journal-title":"COPD J Obstruct Lung Dis"},{"key":"10.1378\/chest.130.4.1117_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1378\/chest.130.4.1117_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQoL, Group EuroQol: a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1378\/chest.130.4.1117_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol, Group EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1378\/chest.130.4.1117_bib22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol Health States","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1378\/chest.130.4.1117_bib23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.130.4.1117_bib24","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure for chronic airflow limitation: the St George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.130.4.1117_bib25","first-page":"A211","article-title":"Relationship between change in St George\u2019s Respiratory Questionnaire scores and patient\u2019s perception of treatment efficacy after one year of therapy with nedocromil sodium [abstract]","volume":"149","author":"Jones","year":"1994","journal-title":"Am Rev Respir Crit Care Med"},{"key":"10.1378\/chest.130.4.1117_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1378\/chest.130.4.1117_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1378\/chest.130.4.1117_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1183\/09031936.03.00101203","article-title":"Do GOLD stages of COPD severity really correspond to differences in health status?","volume":"22","author":"Antonelli-Incalzi","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.130.4.1117_bib30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0895-4356(03)00208-7","article-title":"The influence of COPD on health-related quality of life independent of the influence of comorbidity","volume":"56","author":"Van Manen","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1378\/chest.130.4.1117_bib31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/thx.52.10.879","article-title":"Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting","volume":"52","author":"Harper","year":"1997","journal-title":"Thorax"},{"key":"10.1378\/chest.130.4.1117_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1026475531996","article-title":"Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease","volume":"8","author":"Stavem","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1378\/chest.130.4.1117_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A comparison of the EQ-5D and SF-6D across seven patient groups","volume":"14","author":"Brazier","year":"2004","journal-title":"Health Econ"},{"key":"10.1378\/chest.130.4.1117_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00005650-200503000-00004","article-title":"Valuations of EQ-5D health states: are the United States and United Kingdom different?","volume":"43","author":"Johnson","year":"2005","journal-title":"Med Care"},{"key":"10.1378\/chest.130.4.1117_bib35","article-title":"A comparison of the EQ-5D preference weights predicted by the D1 (US) and the N3 (UK) models","author":"Luo","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1378\/chest.130.4.1117_bib36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body mass index, airflow obstruction, dyspnea and excercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.130.4.1117_bib37","author":"Bonsel","year":"2003","journal-title":"Mild Diseases & Ailments Study (MiDAS): Ziektelastbepaling van 27 vermoedelijk \u2018lichte\u2019 ziekten ten behoeve van rationale beperking van het geneesmiddelenpakket: samenvatting"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215511483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215511483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T13:52:14Z","timestamp":1547301134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215511483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0012369215511483"],"URL":"https:\/\/doi.org\/10.1378\/chest.130.4.1117","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}